New Board Members
by Becky Burns, Vice Chair, Hemophilia Alliance Board

The mission of the Hemophilia Alliance is to work “to ensure member Hemophilia Treatment Centers have the expertise, resources and public support to sustain their integrated clinical and pharmacy services for individuals with bleeding and clotting disorders”. Per the Hemophilia Alliance by-laws, “The Board of Directors should, to the extent feasible, include members representative of the eight (8) regional networks of hemophilia treatment centers, types of programs, expertise, and experience.”

We want to sincerely thank all applicants for their interest in serving on the board. We received a robust slate of candidates who all would have brought something unique to the board. We thoughtfully reviewed and considered all applicants in the context of the Mission and by-laws, seeking to represent our membership most broadly as well as diversify our expertise and insight to most strategically address challenges to further our mission.

We are pleased to announce Rebecca Kruse-Jarres, MD, Sachiko Suzuki, and Miguel Escobar, MD have been elected to serve on the Board, with their terms beginning June 2023. Dr. Kruse-Jarres currently serves as the Medical Director and Executive Director of the Washington Center for Bleeding Disorders as well as Medical Director of the Mountain States Region. Sachiko Suzuki is the 340B Manager and Research Manager at the UCSF Hemophilia Treatment Center. Dr. Escobar is the Medical Director of the Gulf States Hemophilia and Thrombophilia Center. All three new board members bring varied areas of expertise to our board as well as provide representation on the board from all eight regions! We are happy to welcome them to the board and look forward to working with them as we work to support the Hemophilia Alliance team in furthering our mission.

Again, we can’t thank the individuals who applied to serve on the board enough. We may be reaching out to you to assist in serving the Alliance in other ways.